Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.40 |
| ▸ | DRD4 | P21917 | 5/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7773505 | 0.99 | DRD2 (0.42) | DRD2DRD4GPR84ADRB2ADRB1 | |
| SCHEMBL5953495 | 0.79 | TP53 (0.40) | DRD2DRD4GPR84HTTLMNA | |
| SCHEMBL5953124 | 0.78 | DRD2 (0.40) | DRD2DRD4GPR84KDM4ELMNA | |
| SCHEMBL5953729 | 0.77 | DRD2 (0.44) | DRD2DRD4GPR84ALDH1A1KDM4E | |
| SCHEMBL8892605 | 0.77 | DRD2 (0.40) | DRD2DRD4GPR84LMNA | |
| Hydrochloric Acid SCHEMBL9056904 | 0.77 | DRD2 (0.40) | DRD2DRD4GPR84LMNAKMT2A | |
| SCHEMBL4617636 | 0.77 | DRD2 (0.40) | DRD2DRD4GPR84LMNA | |
| Hydrochloric Acid SCHEMBL7769530 | 0.76 | DRD2 (0.39) | DRD2DRD4GPR84LMNA | |
| SCHEMBL5953253 | 0.76 | KMT2A (0.40) | DRD2DRD4GPR84ALDH1A1KDM4E | |
| SCHEMBL5953525 | 0.72 | DRD2 (0.41) | DRD2DRD4GPR84ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100269-A1 | Use of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders | LAMBROU GEORGE N | 2006-05-11 | — | — | US | claimed |
| EP-1589963-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ B,F OXEPINES FOR THE TR EATMENT OF DEGENERATIVE OCULAR DISORDERS | Novartis AG (CH) | 2005-11-02 | — | — | EP | claimed |
| WO-2004066993-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ[B,F]OXEPINES FOR THE TREATMENT OF DEGENERATIVE OCULAR DISORDERS | NOVARTIS AG (CH) | 2004-08-12 | — | — | WO | claimed |
| EP-0726265-B1 | 10-Aminoaliphatyl-dibenz(b,f)oxepins with antineurodegenarative activity | NOVARTIS AG (CH) | 2001-07-25 | — | — | EP | claimed |
| EP-0726265-A1 | 10-Aminoaliphatyl-dibenz(b,f)oxepins with antineurodegenarative activity | CIBA-GEIGY AG (CH) | 1996-08-14 | — | — | EP | claimed |
| US-20060100269-A1 | Use of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders | LAMBROU GEORGE N | 2006-05-11 | — | — | US | disclosed |
| EP-1589963-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ B,F OXEPINES FOR THE TR EATMENT OF DEGENERATIVE OCULAR DISORDERS | Novartis AG (CH) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004066993-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ[B,F]OXEPINES FOR THE TREATMENT OF DEGENERATIVE OCULAR DISORDERS | NOVARTIS AG (CH) | 2004-08-12 | — | — | WO | disclosed |
| EP-0726265-B1 | 10-Aminoaliphatyl-dibenz(b,f)oxepins with antineurodegenarative activity | NOVARTIS AG (CH) | 2001-07-25 | — | — | EP | disclosed |
| EP-0726265-A1 | 10-Aminoaliphatyl-dibenz(b,f)oxepins with antineurodegenarative activity | CIBA-GEIGY AG (CH) | 1996-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100269-A1 | Use of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders | DBH, MAOB, AADAT | DRD2 28/4885DRD4 79/4885GPR84 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.